Sandra Beaver Sells 1,586 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 1,586 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.85, for a total transaction of $17,208.10. Following the completion of the transaction, the chief financial officer now directly owns 146,916 shares in the company, valued at approximately $1,594,038.60. This represents a 1.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Evolus Stock Performance

NASDAQ:EOLS opened at $11.09 on Friday. The firm has a 50-day moving average of $13.46 and a two-hundred day moving average of $13.73. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market cap of $702.23 million, a P/E ratio of -12.19 and a beta of 1.27. Evolus, Inc. has a 1-year low of $9.80 and a 1-year high of $17.82.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EOLS. Bank of New York Mellon Corp increased its holdings in Evolus by 24.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock worth $1,965,000 after purchasing an additional 35,760 shares during the last quarter. Rhumbline Advisers grew its position in shares of Evolus by 27.3% during the second quarter. Rhumbline Advisers now owns 81,439 shares of the company’s stock worth $884,000 after buying an additional 17,442 shares in the last quarter. Arizona State Retirement System grew its position in shares of Evolus by 9.4% during the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after buying an additional 1,253 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Evolus in the second quarter worth $43,000. Finally, Sei Investments Co. raised its holdings in Evolus by 9.8% in the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock valued at $367,000 after acquiring an additional 3,020 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

EOLS has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Barclays upped their target price on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a report on Monday, September 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Friday, September 13th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.